Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS From Taro

Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS From Taro


Strongbridge Biopharma plc, , a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has acquired the U.S. rights to KEVEYISA from a subsidiary of Taro Pharmaceutical Industries Ltd. . KEVEYIS was approved by the U.S. Food and Drug Administration in August 2015 to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis, which is a group of rare hereditary disorders that causes potentially severe episodes of muscle weakness and/or paralysis.



from Biotech News